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Background: Immigrants from South Asia to Western countries have a high prevalence of type 2 diabetes mellitus
(T2DM). We explored pathogenic factors that might contribute to the high risk of T2DM in Pakistani immigrants to
Norway.
Methods: A cross-sectional study was performed in 18 Pakistani and 21 Norwegian men and women with T2DM
(age 29 – 45 years), recruited from two hospital out-patient clinics. Anthropometrics and a two-step euglycemic,
hyperinsulinemic clamp with measurements of non-esterified fatty acids (NEFA) during clamp, was performed in all
patients. Insulin sensitivity, given as the Glucose Infusion Rate (GIR) and Insulin Sensitivity Index (ISI), was calculated
from the two euglycemic clamp steps. Fasting adipokines and inflammatory mediators were measured. Continuous
variables between groups were compared using Student’s t test or Mann–Whitney U test as appropriate.
Spearman’s correlation coefficient and multiple linear regression analyses were used.
Results: Despite having a lower BMI, Pakistani patients were more insulin resistant than Norwegian patients, during
both low and high insulin infusion rates, after adjustment for sex and % body fat: median (interquartile range) GIR
(low insulin): 339.8(468.0) vs 468.4(587.3) μmol/m2/min (p = 0.060), ISI(low insulin): 57.1(74.1) vs 79.7(137.9) μmol/m2/min
(p = 0.012), GIR(high insulin): 1661.1(672.3) vs 2055.6(907.0) μmol/m2/min (p = 0.042), ISI(high insulin): 14.2(7.3) vs 20.7(17.2)
μmol/m2/min (p = 0.014). Pakistani patients had lower percentage NEFA suppression 30 minutes into clamp
hyperinsulinemia than Norwegians: 41.9(90.6)% vs 71.2(42.1)%, (p = 0.042). The relationship of ISI to BMI, leptin and
interleukin-1 receptor antagonist also differed between Norwegians and Pakistanis.
Conclusions: Compared with Norwegian patients, Pakistani patients with T2DM had lower insulin sensitivity,
affecting both glucose and lipid metabolism. The relation of insulin sensitivity to BMI and some adipokines also
differed between the groups.
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Immigrants from South Asia to Western countries have
a high prevalence of Type 2 diabetes mellitus (T2DM)
[1-4]. The prevalence is also high in urban areas in their
countries of origin [5-7]. Studies comparing non-diabetic
subjects from India and the US indicate that Indians
have lower insulin sensitivity [8,9]. Norway, like many
other Western countries, has a growing population of
immigrants, with one of the largest groups being of
Pakistani origin. This group has an alarming prevalence
of T2DM, manifesting at a younger age than in ethnic
Norwegians [10], and reaching more than 25% in 30–
60 year old South Asian women living in an Eastern sub-
urb of Oslo [11]. Better knowledge through studies of
the pathophysiology of T2DM in this population is
necessary to develop more efficient prevention and treat-
ment strategies. Such studies could also give new insight
into the pathogenesis of T2DM in general.
There is a well known association between obesity and
T2DM, but South Asians develop T2DM at lower levels
of body mass index (BMI) than Westerners, and are
more insulin resistant for any given BMI [12,13]. Several
studies have indicated that, in individuals from South
Asia, BMI may be inferior to other measures of adiposity
as a predictor of metabolic risk [13-15].
Adipokines and inflammatory mediators derived from
adipose tissue may be important in the pathogenesis of
insulin resistance and T2DM [16]. Possible differences
in the profile of these substances between South Asians
and Westerners with T2DM, could potentially help
explain differences in the development of T2DM in
these groups.
In the present study, we investigated a group of young
adult immigrants from Pakistan with T2DM, and com-
pared them to a group of Norwegian patients of similar
age. We chose to study young adult subjects, where dis-
ease duration was relatively short, to avoid comorbidities
that might confound the interpretation of our data. Our
aim was to explore differences between the groups with
regards to pathogenic factors such as insulin resistance,
obesity and inflammation, which might contribute to the
high prevalence of T2DM in Pakistani immigrants to
Norway.
Methods
Design
This was a cross-sectional study comparing young T2DM
patients from two different ethnic groups.
Patients
Norwegian and Pakistani patients withT2DM, aged 45 years
or younger, attending the out-patient clinics at Lovisenberg
Deaconess Hospital between 1999 and 2005, and Aker
University Hospital between 2003 and 2009,were eligiblefor inclusion. After searches in the two hospitals’ patient
registries, 195 patients were randomly selected to receive
an invitation to participate in the study. Exclusion criteria
were: ethnicities other than Norwegian or Pakistani, posi-
tive GAD or IA2 auto-antibodies, age > 45 years, person
unwilling or unable to give informed consent. Patients were
contacted by letter with information about the study in
Norwegian and Urdu, and patients whose telephone num-
ber could be obtained were also informed by phone. Nine-
teen Pakistani and 21 Norwegian sex-matched patients (age
29–45 years, 49% men) with confirmed T2DM, agreed to
participate, and were included in the study. Participant
characteristics were similar to a subgroup of approximately
80 of the 155 patients not included, where data on HbA1c
and anthropometrics were available. All Pakistani partici-
pants were first generation immigrants. One Pakistani
woman was excluded on the first day of testing, because of
difficulties in obtaining intravenous access. The remaining
39 patients were examined.
Anthropometrical measurements
Height and weight were measured with participants
wearing light clothing and without any shoes on. Waist
and hip circumferences were assessed with a tape meas-
ure at mid point between the lowest rib margin and the
iliac crest, and at the level of the major trochanter,
respectively. Bioelectrical impedance analysis (BIA) was
performed on a Tanita Body Composition Analyzer BC-
418 (Tokyo, Japan). All subjects were fasting and voided
urine before measurement.
Euglycemic clamp
To enhance comparability of examinations, all patients
stopped taking oral antidiabetic drugs for two days, and
insulin for at least 12 hours prior to examination. Pa-
tients were asked to refrain from strenuous physical
exercise and alcohol intake during these two days, and
to fast from midnight during the night before the exam-
ination. We performed a euglycemic, hyperinsulinemic
clamp, using a modification of the method originally
described by De Fronzo et al. [17]. The clamp was
performed with two steps, first administering a primed,
continuous insulin dose of 40 mU/m2/min for a mini-
mum of 100 minutes, until at least 30 minutes of stable
euglycemia was obtained. This was directly followed by a
400 mU/m2/min insulin infusion, also for a minimum
of 100 minutes, with at least 30 minutes of stable
euglycemia at the end. The body surface area was calcu-
lated using Mostellers equation [18].
Human insulin (Actrapid®, Novo Nordisk, Bagsvaerd,
Denmark) 300 mU/mL and Glucose 200 mg/mL were
infused through a teflon catheter in a vein at the left
elbow of the patient. Insulin was diluted in NaCl 0.9%,
after having first added 2 ml of the patients own blood,
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blood samples were drawn from a teflon catheter in a
vein at the right elbow, kept open by a slow infusion of
NaCl 0.9%. The right arm was kept at 37°C by a heating
sleeve connected to a thermal control unit (Swetron AB,
Veddestad, Sweden), to arterialize blood samples. Plasma
glucose was measured every five minutes using a
OneTouch Ultra glucose measuring device (LifeScan,
Milpitas, CA), with control measurements every 30
minutes by the glucose oxidase method, on a Glucose
Analyzer II (Beckman Instruments, Fullerton, CA). At
the end of each step of the clamp, three measurements
of serum insulin were taken at ten-minute intervals. The
glucose infusion rate in μmol/m2/min was established,
and denoted GIR40 and GIR400 respectively. Because of
varying metabolic clearance rates of insulin, the insulin
levels measured at the end of each step of the clamp
differed between patients. The insulin sensitivity index
(ISI) was therefore also calculated, and expressed as the
ratio of the GIR to the prevailing mean serum insulin
levels ((GIR/I) × 100), denoted ISI40 and ISI400. Every
30 minutes during the 2 step euglycemic clamp, EDTA
plasma for non-esterified fatty acid (NEFA) measure-
ments was extracted and immediately frozen at −70°C.
Two Norwegian and two Pakistani patients did not at-
tain euglycemia during the first step of the clamp, and
were excluded from this part of the clamp analyses. Two
Norwegian and four Pakistani patients were not examined
with the high-step clamp, due to contraindication of hy-
perosmolar glucose at high infusion rates (for the most
insulin sensitive patients) and long duration of the low-
step part of the clamp to reach euglycemia (for the most
insulin resistant patients). After excluding these patients
from clamp analyses, there were 46% men in the first step
and 48% men in the second step of the clamp.
Blood samples
Fasting plasma glucose was measured by the glucose
oxidase method on a Glucose Analyzer II (Beckman Instru-
ments). Serum insulin was analyzed using the radio-
immunoassay (RIA) kit, formerly from Linco Research Inc.
(St. Charles, MO), presently available from Millipore Corp.
(Billerica, MA). Plasma HbA1c was measured by high
performance liquid chromatography on a Variant analyzer
(Bio-Rad, Richmond, CA). Fasting serum total cholesterol,
serum HDL cholesterol, and serum triglycerides were
measured using a routine enzymatic method (Roche Diag-
nostics, Mannheim, Germany). Serum LDL cholesterol
was calculated using the Friedewald equation [19]. NEFA
were analyzed using a NEFA C enzymatic color test kit,
(Wako Chaemicals GmbH, Neuss, Germany), modified to
run on a Technicon RA1000 (Technicon Instruments
Corp., Tarrytown, NY). Plasma levels of adiponectin and
leptin were analyzed using RIA kits from Millipore Corp.(Billerica, MA),(also formerly from Linco Research Inc.
(St. Charles, MO)). Plasma measurements of soluble
tumor necrosis factor-receptor type 1 (sTNF-R1) and high
sensitive C-reactive protein (hsCRP) were performed using
DuoSet ELISA kits from R&D Systems (Minneapolis, MN).
Plasma measurements of interleukin-1 receptor antagonist
(IL-1RA) were performed using CytoSet from Invitrogen
Corporation (Carlsbad, CA), with streptavidin-horseradish
peroxydase from R&D Systems. Plasma measurements of
interleukin-6 (IL-6) were performed using a High Sensi-
tivity ELISA kit from Abcam plc. (Cambridge, UK).
Statistical analysis
Data are presented as mean ± SD, or median (interquartile
range) as appropriate. We analysed non-normally dis-
tributed data log-transformed, or with the use of non-
parametric methods. Student’s t test or Mann Whitney U
tests were used for comparison of continuous variables
between groups. For correlations, Spearman’s correlation
coefficient (rs) was used. Multiple linear regression analyses
were performed with log-transformation of parameters
when needed, to obtain normally distributed residuals. A
two-sided p-value <0.05 was considered significant, but
owing to the large number of comparisons, particular atten-
tion should be directed towards analyses where p-values
are <0.01. Statistical analyses were performed with SPSS
18.0 for Windows (SPSS Inc., Chicago, IL).
Ethics
The study was carried out in accordance with the
Helsinki Declaration, and approved by the Eastern
Norway Regional Committee for Medical and Health
Research Ethics. Informed, written consent was obtained
from each participant before enrolment.
Results
Ethnic differences in diabetes duration and
anthropometrics
The two ethnic groups did not differ significantly in age,
sex and fasting plasma glucose. In contrast, BMI and
weight, including both total body fat mass and lean body
mass were significantly higher in the Norwegian, com-
pared with the Pakistani group (Table 1). Despite lower
BMI, Pakistani patients had higher median HbA1c, longer
median duration of diabetes, and a tendency towards earl-
ier onset of diabetes (reported mean age at onset 30 years
vs 34 years, p = 0.06). Further clinical characteristics of the
participating patients are presented in Additional file 1.
Ethnic differences in insulin sensitivity
When examining insulin sensitivity with a two-step
euglycemic, hyperinsulinemic clamp, median values for
GIR and ISI showed consistently higher point estimates
in the Norwegian compared to the Pakistani group,
Table 1 Clinical characteristics of patients according to
ethnic group
Norwegians Pakistanis
n = 21 n = 18 p
Males (%) 10 (48%) 9 (50%)
Age (years) 42 (6) 41 (8) 0.865
Years with diabetes 5 (9) 9 (7) 0.021
Weight (kg) 106.8 ± 13.6 90.1 ±23.4 0.009
BMI (kg/m2) 37.2 (6.0) 30.9 (9.4) 0.008
Waist circumference (cm) 114.3 ± 10.9 106.5 ±17.4 0.102
Waist-hip ratio 1.00 ± 0.09 1.01 ± 0.09 0.575
Total body fat (%) 36.9 ± 9.6 34.2 ± 7.7 0.395
Total body fat mass (kg) 39.5 ± 12.0 28.0 ± 8.2 0.005
Lean body mass (kg) 67.1 ± 12.6 54.2 ± 12.2 0.007
Fasting plasma glucose
(mmol/l)
10.7 ± 3.2 10.6 ± 3.3 0.973
HbA1c (%/mmol/mol) 7.3/56 (1.4/13) 8.7/72 (2.9/31) 0.022
Fasting insulin (pmol/l) 166 (160) 209 (193) 0.405
Fasting C-peptide (pmol/l) 1162 ± 458 977 ± 373 0.193
Total cholesterol (mmol/l) 4.5 ± 1.0 4.7 ± 1.3 0.512
HDL cholesterol (mmol/l) 1.03 ± 0.21 1.08 ± 0.24 0.557
LDL cholesterol (mmol/l) 2.7 ± 0.8 2.6 ± 0.6 0.868
Triglycerides (mmol/l) 1.6 (1.1) 1.4 (1.1) 0.832
Table 1: For normally distributed parameters, mean ± SD is given, and
comparisons were made using Student’s t test. For non-normally distributed
parameters, median (interquartile range) is given, and comparisons were made
using the Mann–Whitney U test. Median HbA1c-values are reported as NGSP-
%/IFCC-mmol/mol with interquartile range in parentheses. In bold: p < 0.05.
Table 2 Insulin sensitivity and NEFA suppression
Norwegians Pakistanis p
GIR40 468.4 (587.3) 339.8 (468.0) 0.456
ISI40 79.7 (137.9) 57.1 (74.1) 0.289
S-insulin end low step
(pmol/l)
546 (336) 715 (243) 0.041
GIR400 2055.6 (907.0) 1661.1 (672.3) 0.080
ISI400 20.7 (17.2) 14.2 (7.3) 0.016
S-insulin end high step
(pmol/l)
9505 (2738) 11082 (2922) 0.069
Fasting p-NEFA
(mmol/l)
0.59 (0.43) 0.50 (0.29) 0.394
NEFA suppression
0–30 minutes (%)
71.2 (42.1) 41.9 (90.6) 0.042
Table 2: Data are presented as median (interquartile range), and comparisons
are made using the Mann–Whitney U test. In bold: p < 0.05. GIR40 = glucose
infusion ratelow step, ISI40 = glucose infusion rate/s-insulinlow step, GIR400 =
glucose infusion ratehigh step, ISI400 = glucose infusion rate/s-insulinhigh step. GIR
is expressed as μmol/m2/min, and ISI as 100 × μmol/m2/min/s-Ins. NEFA =
non-esterified fatty acids. Number of Norwegians and Pakistanis were: during
the low step, n = 19 and 16, respectively. During the high step, n = 19 and 14,
respectively, and for NEFA measurements, n = 13 and 15, respectively.
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ences between the groups in GIR or ISI during the first
step (Table 2). However, when adjusting for sex and %
TBF in a multiple regression analysis, LogGIR40 showed a
clear tendency towards lower values in the Pakistani
group, and LogISI40 was significantly lower in the
Pakistani compared to the Norwegian group (Table 3).
Further adjustment for BMI, HbA1c or diabetes duration
did not change the relation of ISI40 or GIR40 to ethnicity.
Ethnicity, sex and % TBF together explained 55% of the
variation in insulin sensitivity, expressed as ISI40. During
the second step of the clamp, Pakistani patients had non-
significantly lower median GIR400, and significantly lower
ISI400 (Table 2). In standard multiple regression analyses,
ethnicity and % TBF explained 29% of ISI400 and 24% of
GIR400 variation (Table 3). Sex was no longer a significant
predictor of LogISI400 or Log GIR400, and neither was
BMI, diabetes duration or HbA1c.
Ethnic differences in the relation of BMI and waist
circumference to insulin sensitivity
When exploring the relationships between anthropomet-
ric characteristics and insulin sensitivity, we found astrong, significant correlation between ISI40 and BMI in
the Norwegian group, and a weaker, non significant cor-
relation in the Pakistani group. Waist circumference,
however was significantly correlated with ISI40 in the
Pakistani, but not in the Norwegian group (Figure 1a-b
and Additional file 2). There was also a significant in-
teraction between ethnicity and LogBMI (p = 0.032) in a
multiple regression analysis, suggesting a difference be-
tween the ethnic groups. (Dependent variable: LogISI40,
independent variables: ethnicity (p = 0,026), LogBMI (p =
0,004), as well as ethnicity x LogBMI). We were, however,
not able to confirm an ethnic difference in the relationship
between insulin sensitivity and waist circumference by
regression analysis (data not shown).
Ethnic differences in suppression of non-esterified
fatty acids
There were no significant differences in fasting NEFA
values between Norwegian and Pakistani patients, but
initial NEFA suppression by hyperinsulinemia, expressed
as percentage suppression of NEFA after 30 minutes
of the clamp, was significantly more pronounced in
the Norwegian group compared to the Pakistani group
(Figure 2, Table 2).
Adipokines and markers of inflammation
Table 4 shows levels of adipokines and markers of
inflammation in the two ethnic groups. The Norwegian,
but not the Pakistani group, showed negative cor-
relations between ISI40 and leptin, as well as IL-1RA
(Additional file 2). Fasting IL-1RA was significantly posi-
tively correlated to BMI in both patient groups. In the
Norwegian group it was also positively correlated to
Table 3 Multiple regression analyses of insulin sensitivity
Variable Adjusted effect β 95% CI p-value Adjusted effect β 95% CI p-value
Model A: LogISI40 LogGIR40
Ethnicity −0.335 (−0.588, -0.081) 0.012 −0.210 (−0.429, 0.010) 0.060
Sex −0.726 (−1.129, -0.322) 0.001 −0.455 (−0.804, -0.106) 0.013
% body fat −0.061 (−0.084, -0.037) <0.001 −0.044 (−0.065, -0.024) <0.001
Model A + BMI 0.008 (−0.015, 0.031) 0.464 0.002 (−0.017, 0.022) 0.803
Model A + HbA1c −0.009 (−0.095, 0.078) 0.835 −0.038 (−0.111, 0.036) 0.300
Model A + Diabetes duration −0.001 (−0.028, 0.026) 0.941 0.005 (−0.019, 0.028) 0.697
Model B: LogISI400 Log GIR400
Ethnicity −0.186 (−0.333, -0.040) 0.014 −0.117 (−0.229, -0.005) 0.042
% body fat −0.009 (−0.017, 0.000) 0.040 −0.007 (−0.013, 0.000) 0.043
Model B + Sex −0.163 (−0.394, 0.068) 0.158 −0.081 (−0.262, 0.101) 0.369
Model B + BMI 0.005 (−0.007, 0.018) 0.378 0.005 (−0.004, 0.014) 0.295
Model B + HbA1c 0.005 (−0.045, 0.055) 0.829 −0.013 (−0.051, 0.025) 0.493
Model B + Diabetes duration −0.008 (−0.023, 0.007) 0.304 −0.007 (−0.019, 0.005) 0.231
Table 3: Dependent variables in model A: LogISI40 or LogGIR40. Constant for Log ISI40 = 4.428. R
2: 0.55. Constant for LogGIR40 = 4.464. R
2: 0.48. Reference group for
ethnicity = Norwegians, for sex = women. Variables excluded from final models: BMI, HbA1c(NGSP) and diabetes duration.
Dependent variables in model B: LogISI400 or LogGIR400. Constant for Log ISI400 = 1.650. R
2: 0.29. Constant for LogGIR400 = 3.558. R
2: 0.24. Variables excluded from
final models: sex, BMI, HbA1c and diabetes duration. In bold: p < 0.05.
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neither correlated to ISI, nor to leptin (rs = 0.14, p =
0.593), but correlated positively to waist circumference.
Discussion
In the present study we found significant differences in
insulin sensitivity, measured by the euglycemic, hype-
rinsulinemic clamp, between young adult Norwegian
and Pakistani patients with T2DM. There were also eth-
nic differences in diabetes duration and HbA1c, even in
this young patient population, demonstrating longer
duration of diabetes and poorer glycemic control in the
Pakistani group. These differences, however, did not
explain the lower insulin sensitivity in the Pakistani
group per se, since neither HbA1c nor diabetes duration
were significantly associated with the ethnic differences
found in insulin sensitivity in adjusted multiple regres-
sion analyses.
Furthermore, we demonstrated a different relationship
between insulin sensitivity and BMI in the two groups.
Although obesity is clearly an important factor in insulin
resistance, BMI was a poor marker of metabolic distur-
bances in the Pakistani patients. Whereas Pakistani pa-
tients were all quite insulin resistant regardless of BMI,
among the Norwegian patients there was a strong ne-
gative correlation between BMI and insulin sensitivity.
To our knowledge, this is the first study, using the
euglycemic clamp to measure insulin sensitivity, to show
such ethnic differences in subjects with T2DM. Our re-
sults support and expand previously published results
obtained in healthy South Asian immigrants [20,21].NEFA are normally suppressed by hyperinsulinemia.
There is evidence that this suppression is impaired in
T2DM [22], although this has not been found by all
authors [23]. Our study shows similar fasting NEFA
values between the two ethnic groups, but significantly
slower NEFA suppression in the Pakistani group, despite
higher fasting and end-clamp serum insulin levels. Some
evidence of ethnic differences, both in fasting NEFA
levels and degree of suppression by hyperinsulinemia,
has previously been shown in non-diabetic subjects [24].
Other authors, however, found no difference in NEFA
suppression according to ethnicity [25]. Our findings
further support that impaired insulin sensitivity affects
lipid metabolism more severely in Pakistani patients as
compared to Norwegian patients with T2DM.
It is noteworthy that leptin and IL-1RA were differently
related to insulin sensitivity in the two ethnic groups.
T2DM is now regarded as a disorder characterized by
non-resolving inflammation. IL-1, released though acti-
vation of Nod-like receptor protein 3 (NLRP3) infla-
mmasomes, seems to play an important role in the
inflammatory processes [26]. Il-1RA is considered an anti-
inflammatory cytokine, that antagonizes IL-1β and IL-1α,
and is elevated, at least in part, in response to elevation of
these inflammatory cytokines. An early study showed de-
creased IL-1RA levels in type 2 diabetes [27], and it has
been demonstrated that Leptin decreases β-cell produc-
tion of IL-1RA, down-regulating IL-1RA expression in
pancreatic β-cells in type 2 diabetes [28]. However, more
recent studies have shown high levels of IL-1RA in obes-
ity, correlating with BMI, insulin resistance and serum
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Figure 1 Relation between ISI40, BMI and waist circumference.
Relation of insulin sensitivity, expressed as ISI40, to a) body mass
index (BMI) and b) waist circumference in Norwegian (black
diamonds) and Pakistani (white circles) patients with type 2 diabetes.
Solid regression lines represent Norwegian patients and dashed lines
represent Pakistani patients. Spearman’s Correlation coefficients (rs)
and p-values for each correlation are presented for both ethnicities.
In a) the correlations have been performed both including and
omitting the outlier (BMI 59). They give approximately the same
result, and the outlier is excluded in the rs presented, but shown in
the scatterplot.
-0,2
0
0,2
0,4
0,6
0,8
1
1,2
0 30 60 90 120
St
an
da
rd
iz
ed
 v
al
ue
s 
of
 N
EF
A 
Time (minutes)
*
Figure 2 Suppression of NEFA during euglycemic clamp.
Non-esterified fatty acid (NEFA) values have been standardized, with
fasting values set to 1.0. The figure shows standardized mean (SD)
values of NEFA during the first 120 minutes of the low step
euglycaemic clamp, for both patient groups. Norwegian patients are
shown in black diamonds with solid lines. Pakistani patients are
shown in white circles with dashed lines. *p < 0.05.
Table 4 Adipokines and markers of inflammation
Norwegians Pakistanis p-value
Adiponectin (μg/ml) 4.6 (4.4) 3.3 (3.4) 0.15
Leptin (pmol/l) 950 (1043) 907 (1014) 0.89
IL-6 (pg/ml) 1.18 (1.19) 1.07 (2.18) 0.43
hsCRP (pg/ml) 2.31 (3.48) 2.45 (2.46) 0.63
IL-1RA (pg/ml) 62.75 (98.10) 45.90 (103.95) 0.36
sTNF-R1 (ng/ml) 1.04 (0.20) 0.92 (0.31) 0.14
Table 4: Data are presented as median (interquartile range), and comparisons
are made using the Mann–Whitney U test. Nor = Norwegian patients. Pak =
Pakistani patients.The number of Nor/Pak were: for adiponectin and leptin,
n = 21/18. For IL-6, hsCRP and IL-1RA, n = 20/17, and for sTNF-R1, n = 20/16.
IL-6 = interleukin-6, hsCRP = high sensitive C-reactive protein, IL-1RA =
interleukin-1 receptor antagonist, sTNF-R1 = soluble tumor necrosis
factor-receptor 1.
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pose tissue in obese humans [29-31]. Subjects with im-
paired glucose tolerance have higher levels of IL-1RA [32],
and in two prospective cohort studies, IL-1RA was found
to be elevated several years before diabetes diagnosis, and
significantly predicted incident diabetes [33,34]. Whether
this represents a counteracting mechanism in response toIL-1, which circulates at much lower levels in plasma and
is more difficult to detect in clinical samples, is at present
unclear. In our study, leptin as well as IL-1RA was nega-
tively associated with insulin sensitivity in the Norwegian,
but not the Pakistani patients. Leptin and IL-1RA corre-
lated with BMI in both groups, and with waist circumfer-
ence in the Pakistani group only. These findings, together
with the different relationship between insulin sensitivity
and BMI demonstrated in our two groups, suggest that
there may be important differences in the relationship
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regulation of these signal molecules between the two eth-
nic groups. As leptin is known to correlate mainly to
superficial abdominal adipose tissue [35,36], our findings
could indicate that ethnic differences exist in the meta-
bolic activity of the different compartments of abdominal
adipose tissue.
The main strengths of our study include thorough pa-
tient examinations with gold standard methods for
measurement of insulin sensitivity, and using two steps
of hyperinsulinemia. The difference in HbA1c and dia-
betes duration between the two patient groups may be
regarded as a weakness. However, these differences were
also present in patients who were not included in the
study, and have been demonstrated in several other
studies [10-12]. Thus, an attempt to match for these pa-
rameters could in our opinion have created a selection
bias. It can nevertheless be regarded as a limitation to
our study that patients were recruited from a popula-
tion referred to hospital outpatient diabetes clinics, and
that sample size was limited, increasing the risk of type
II statistical errors. Recruitment of patients, especially
the Pakistani patients, proved challenging, which ex-
plains why only 20% of the invited patients participated.
While a larger and more representative cohort would
have strengthened our study, we note that the ethnic
differences in insulin sensitivity showed consistent pat-
terns for all four estimates of insulin sensitivity. This
also corresponds well with the clinical picture of higher
diabetes prevalence and poorer glycemic control appar-
ent in South Asian populations. We did not measure
endogenous glucose production during the euglycemic
clamp, and our glucose infusion rates may therefore
underestimate the true peripheral glucose uptake, at
least during the low insulin infusion level. Lastly, body
composition was measured by BIA, which may be less
accurate than dual x-ray absorptiometry, computed
tomography or magnetic resonance imaging. BIA is,
however, an inexpensive and accessible way of estimat-
ing body composition, which is gaining use in clinical
practice.Conclusions
In this study of Norwegian and Pakistani patients with
T2DM we found significant differences in insulin sensi-
tivity and the relationship between insulin sensitivity and
obesity markers, which may impact on our understand-
ing of the pathogenic mechanisms that place Pakistani
subjects at higher risk of developing T2DM. Further
studies are needed to elucidate a possible relationship
between insulin sensitivity, various adipose tissue com-
partments and adipokines and related molecules in vari-
ous ethnic groups.Additional files
Additional file 1: Table showing. Further clinical characteristics of
patients according to ethnic group.
Additional file 2: Table showing. Correlations between parameters of
insulin sensitivity, anthropometry, adipokines and inflammation.
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